Cargando…
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been link...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945550/ https://www.ncbi.nlm.nih.gov/pubmed/31907006 http://dx.doi.org/10.1186/s13063-019-3758-9 |
_version_ | 1783485200649420800 |
---|---|
author | Gaughran, Fiona Stringer, Dominic Berk, Michael Smith, Shubulade Taylor, David Whiskey, Eromona Landau, Sabine Murray, Robin McGuire, Philip Gardner-Sood, Poonam Wojewodka, Gabriella Ciufolini, Simone Jordan, Harriet Clarke, Jessie Allen, Lauren Krivoy, Amir Stubbs, Brendon Lowe, Philippa Arbuthnott, Maurice Rathod, Shanaya Boardman, Andrew Firdosi, Mudasir McGrath, John J. |
author_facet | Gaughran, Fiona Stringer, Dominic Berk, Michael Smith, Shubulade Taylor, David Whiskey, Eromona Landau, Sabine Murray, Robin McGuire, Philip Gardner-Sood, Poonam Wojewodka, Gabriella Ciufolini, Simone Jordan, Harriet Clarke, Jessie Allen, Lauren Krivoy, Amir Stubbs, Brendon Lowe, Philippa Arbuthnott, Maurice Rathod, Shanaya Boardman, Andrew Firdosi, Mudasir McGrath, John J. |
author_sort | Gaughran, Fiona |
collection | PubMed |
description | BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. METHODS/DESIGN: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. DISCUSSION: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. TRIAL REGISTRATION: ISRCTN, ISRCTN12424842. Registered on 25 February 2015. |
format | Online Article Text |
id | pubmed-6945550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69455502020-01-07 Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial Gaughran, Fiona Stringer, Dominic Berk, Michael Smith, Shubulade Taylor, David Whiskey, Eromona Landau, Sabine Murray, Robin McGuire, Philip Gardner-Sood, Poonam Wojewodka, Gabriella Ciufolini, Simone Jordan, Harriet Clarke, Jessie Allen, Lauren Krivoy, Amir Stubbs, Brendon Lowe, Philippa Arbuthnott, Maurice Rathod, Shanaya Boardman, Andrew Firdosi, Mudasir McGrath, John J. Trials Study Protocol BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. METHODS/DESIGN: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. DISCUSSION: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. TRIAL REGISTRATION: ISRCTN, ISRCTN12424842. Registered on 25 February 2015. BioMed Central 2020-01-06 /pmc/articles/PMC6945550/ /pubmed/31907006 http://dx.doi.org/10.1186/s13063-019-3758-9 Text en © The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Gaughran, Fiona Stringer, Dominic Berk, Michael Smith, Shubulade Taylor, David Whiskey, Eromona Landau, Sabine Murray, Robin McGuire, Philip Gardner-Sood, Poonam Wojewodka, Gabriella Ciufolini, Simone Jordan, Harriet Clarke, Jessie Allen, Lauren Krivoy, Amir Stubbs, Brendon Lowe, Philippa Arbuthnott, Maurice Rathod, Shanaya Boardman, Andrew Firdosi, Mudasir McGrath, John J. Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
title | Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
title_full | Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
title_fullStr | Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
title_full_unstemmed | Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
title_short | Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
title_sort | vitamin d supplementation compared to placebo in people with first episode psychosis - neuroprotection design (dfend): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945550/ https://www.ncbi.nlm.nih.gov/pubmed/31907006 http://dx.doi.org/10.1186/s13063-019-3758-9 |
work_keys_str_mv | AT gaughranfiona vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT stringerdominic vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT berkmichael vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT smithshubulade vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT taylordavid vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT whiskeyeromona vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT landausabine vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT murrayrobin vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT mcguirephilip vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT gardnersoodpoonam vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT wojewodkagabriella vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT ciufolinisimone vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT jordanharriet vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT clarkejessie vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT allenlauren vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT krivoyamir vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT stubbsbrendon vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT lowephilippa vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT arbuthnottmaurice vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT rathodshanaya vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT boardmanandrew vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT firdosimudasir vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial AT mcgrathjohnj vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial |